Research Papers:

Prevalence of human papillomavirus infection and genotyping for population-based cervical screening in developed regions in China

Yanru Zhang, Yueyun Wang, Li Liu, Chun Guo, Zhihua Liu and Shaofa Nie _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:62411-62424. https://doi.org/10.18632/oncotarget.11498

Metrics: PDF 1707 views  |   HTML 2583 views  |   ?  


Yanru Zhang1,*, Yueyun Wang2,*, Li Liu1, Chun Guo1, Zhihua Liu2, Shaofa Nie1

1Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, Hubei, P.R. China

2Shenzhen Maternity and Child Health Hospitals, 518000 Shenzhen, Guangdong, P. R. China

*These authors contributed equally to this work

Correspondence to:

Shaofa Nie, email: [email protected]

Zhihua Liu, email: [email protected]

Keywords: human papillomavirus, prevalence, genotype, cervical screening, China

Received: May 09, 2016    Accepted: July 28, 2016    Published: August 22, 2016


We conducted a cross-sectional analysis to assess the distribution of human papillomavirus (HPV) types and explored an acceptable strategy for cervical screening in Shenzhen, China. A total of 2717 individuals ranging in age from 30–59 years were recruited. Clinical sensitivity and specificity as well as positive (PPV) and negative (NPV) predictive values were estimated. A triage strategy was regarded as acceptable when the NPV was at least 98.0%. 432 (15.9%) participants presented HPV positive. The five most prevalent HPV types were HPV52 (22.9%), HPV16 (12.7%), HPV53 (10.0%), HPV51 (8.6%), and HPV58 (8.1%). The CIN2+ risks for each HPV type were 40.0% for HPV33, 32.4% for HPV16, 18.2% for HPV58, 13.3% for HPV56, and 11.1% for HPV68 in descending order. Baseline cytology testing combined with HPV16/33/52/58 genotyping met the NPV thresholds at 98.6% with a PPV of 17.9%, demonstrating excellent clinical performance for detecting HPV types in CIN2+ patients. In conclusion, triaging HPV-positive women by baseline cytology combined with HPV16/58/33/52 genotyping is an acceptable strategy for cervical cancer screening in Shenzhen, China.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11498